Platelet glycoprotein Ib-IX-V complex and von Willebrand factor (GPIb-IX-V/vWF)

The interaction between von Willebrand factor (vWF) and platelet receptors, primarily the glycoprotein Ib-IX-V (GPIb-IX-V) complex and integrin alpha-IIb beta-3 (GPIIb/IIIa), is a critical mediator of arterial thrombosis and hemostasis [1, 8]. vWF is a large, multimeric glycoprotein that acts as a bridge between the exposed subendothelial matrix and platelets at sites of vascular injury, particularly under high-shear stress conditions [4, 10]. The binding of the vWF A1 domain to the GPIbα subunit of the platelet receptor complex initiates platelet tethering and rolling, which is followed by platelet activation and firm adhesion mediated by other receptors like GPIIb/IIIa [8, 17]. This axis is a major therapeutic target in conditions characterized by microvascular thrombosis, such as thrombotic thrombocytopenic purpura (TTP), where a deficiency in the vWF-cleaving protease ADAMTS13 leads to the accumulation of ultra-large vWF multimers [2, 13]. Drugs targeting this interaction, such as the nanobody caplacizumab, aim to prevent the formation of platelet-rich microthrombi by blocking the vWF-GPIb binding site [7, 9]. Beyond TTP, this target is of significant interest for the development of next-generation antithrombotic therapies for acute coronary syndromes and ischemic stroke [1, 6]. These therapies offer the potential to inhibit pathological thrombosis with a lower risk of bleeding compared to traditional antiplatelet agents [1, 4]. The interaction also triggers intracellular signaling pathways, including Src and PI3K activation, which further amplify the platelet response [16].

Other names

vWF-GPIb axisPlatelet-vWF interactionGlycoprotein Ib-von Willebrand factor complexvWF-GPIb-IX-V interactionPlatelet adhesion receptor complex

Inhibition of the interaction between the von Willebrand factor A1 domain and the platelet glycoprotein Ib-alpha receptor subunit.